Literature DB >> 18579553

Long-term follow-up of prenatally treated children at risk for congenital adrenal hyperplasia: does dexamethasone cause behavioural problems?

Tatja Hirvikoski1, Anna Nordenström, Torun Lindholm, Frank Lindblad, E Martin Ritzén, Svetlana Lajic.   

Abstract

OBJECTIVES: To investigate the long-term effects of prenatal treatment of congenital adrenal hyperplasia (CAH) with emphasis on behavioural problems and temperament.
DESIGN: A population-based long-term follow-up study of Swedish children at risk for virilising CAH, who had received treatment prenatally with dexamethasone (DEX). The questionnaire-based follow-up was performed when the children had reached school age.
METHODS: Standardised parent-completed questionnaires were used to evaluate adaptive functioning, behavioural/emotional problems and psychopathology, social anxiety and temperament in DEX-exposed school-aged children (n=26) and matched controls (n=35). In addition, the association between parental questionnaires and children's self-ratings was investigated.
RESULTS: There were no statistically significant differences between DEX-exposed children and controls in measures of psychopathology, behavioural problems and adaptive functioning. In a questionnaire on temperamental traits, DEX-exposed children were described by their parents as being more sociable than controls (P=0.042). The correlation analysis showed only modest parent-child agreement on social anxiety, i.e. the increased social anxiety in children's self-ratings was not confirmed by their parents.
CONCLUSIONS: DEX-treated children showed good overall adjustment. The parent-child agreement with respect to social anxiety was modest, highlighting the importance of multiple information sources and assessment methods. The clinical significance of the observed difference in sociability cannot be determined within the frameworks of this study. Additional studies of larger cohorts are essential to make more decisive conclusions on the safety of the treatment. Until then, it is important that parents are thoroughly informed about the benefits and potential risks and uncertainties of this controversial treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18579553     DOI: 10.1530/EJE-08-0280

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  20 in total

Review 1.  Prenatal pharmacotherapy for fetal anomalies: a 2011 update.

Authors:  Lisa Hui; Diana W Bianchi
Journal:  Prenat Diagn       Date:  2011-06-03       Impact factor: 3.050

2.  Early dexamethasone treatment induces placental apoptosis in sheep.

Authors:  Thorsten Braun; Wenbin Meng; Hongkai Shang; Shaofu Li; Deborah M Sloboda; Loreen Ehrlich; Karolin Lange; Huaisheng Xu; Wolfgang Henrich; Joachim W Dudenhausen; Andreas Plagemann; John P Newnham; John R G Challis
Journal:  Reprod Sci       Date:  2014-07-25       Impact factor: 3.060

Review 3.  Cooperativity and complementarity: synergies in non-classical and classical glucocorticoid signaling.

Authors:  Ranmal A Samarasinghe; Selma F Witchell; Donald B DeFranco
Journal:  Cell Cycle       Date:  2012-08-01       Impact factor: 4.534

Review 4.  Prenatal treatment of congenital adrenal hyperplasia-not standard of care.

Authors:  Selma Feldman Witchel; Walter L Miller
Journal:  J Genet Couns       Date:  2012-05-26       Impact factor: 2.537

5.  Cognitive outcome of offspring from dexamethasone-treated pregnancies at risk for congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

Authors:  Heino F L Meyer-Bahlburg; Curtis Dolezal; Rita Haggerty; Michael Silverman; Maria I New
Journal:  Eur J Endocrinol       Date:  2012-05-01       Impact factor: 6.664

6.  Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline.

Authors:  Phyllis W Speiser; Ricardo Azziz; Laurence S Baskin; Lucia Ghizzoni; Terry W Hensle; Deborah P Merke; Heino F L Meyer-Bahlburg; Walter L Miller; Victor M Montori; Sharon E Oberfield; Martin Ritzen; Perrin C White
Journal:  J Clin Endocrinol Metab       Date:  2010-09       Impact factor: 5.958

Review 7.  Minireview: the impact of antenatal therapeutic synthetic glucocorticoids on the developing fetal brain.

Authors:  Melanie E Peffer; Janie Y Zhang; Leah Umfrey; Anthony C Rudine; A Paula Monaghan; Donald B DeFranco
Journal:  Mol Endocrinol       Date:  2015-03-12

Review 8.  Congenital adrenal hyperplasia in pregnancy: approach depends on who is the 'patient'.

Authors:  Erin Keely; Janine Malcolm
Journal:  Obstet Med       Date:  2012-09-24

9.  An Evidence-Based Model of Multidisciplinary Care for Patients and Families Affected by Classical Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency.

Authors:  Traci L Schaeffer; Jeanie B Tryggestad; Ashwini Mallappa; Adam E Hanna; Sowmya Krishnan; Steven D Chernausek; Laura J Chalmers; William G Reiner; Brad P Kropp; Amy B Wisniewski
Journal:  Int J Pediatr Endocrinol       Date:  2010-03-18

Review 10.  Challenges in Prenatal Treatment with Dexamethasone.

Authors:  Bonnie McCann-Crosby; Frank Xavier Placencia; Oluyemisi Adeyemi-Fowode; Jennifer Dietrich; Rachel Franciskovich; Sheila Gunn; Marni Axelrad; Duong Tu; David Mann; Lefkothea Karaviti; Vernon Reid Sutton
Journal:  Pediatr Endocrinol Rev       Date:  2018-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.